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The number of immune cells, especially dendritic cells and cytotoxic tumor infiltrating lymphocytes (TIL), particularly
Th1 cells, CD8 T cells, and NK cells is associated with increased survival of cancer patients. Such antitumor cellular
immune responses can be greatly enhanced by adoptive transfer of activated type 1 lymphocytes. Recently, adoptive cell
therapy based on infusion of ex vivo expanded TILs has achieved substantial clinical success. Cytokine-induced killer (CIK)
cells are a heterogeneous population of effector CD8 T cells with diverse TCR specificities, possessing non-MHC-restricted
cytolytic activities against tumor cells. Preclinical studies of CIK cells in murine tumor models demonstrate significant
antitumor effects against a number of hematopoietic and solid tumors. Clinical studies have confirmed benefit and
safety of CIK cell-based therapy for patients with comparable malignancies. Enhancing the potency and specificity of
CIK therapy via immunological and genetic engineering approaches and identifying robust biomarkers of response will
significantly improve this therapy.Introduction
The presence of cytotoxic tumor infiltrating lymphocytes
(TIL) within tumor is associated with increased survival of
cancer patients [1,2]. Both antitumor adaptive and innate
cellular immunity are important for resistance of tumor
growth and eventual elimination of cancer. Theoretically,
antitumor cellular immune responses can be greatly
enhanced by adoptive transfer of lymphocytes, a term
encompassing a strategy in which autologous T or NK
cells are acquired from a cancer patient and then activated
and expanded ex vivo prior to reinfusion. Adoptive cell
therapy of cancer, first demonstrated in mice more than
50 year ago [3], has gained momentum in recent years
due to impressive clinical experiences with melanoma
patients [4]. This approach is based on ex vivo expansion
of large numbers of TILs and selection of tumor-specific
T cell lines. The major effectors of TIL cells are phenotypi-
cally CD3+CD8+ T cells and their anti-tumor functions are
MHC restricted [5]. In contrast to tumor antigen-specific
immunotherapy, there is potential utility of non-antigen
specific cell-based therapy. Many patients with cancer are* Correspondence: jjtnew@163.com; Binfeng@pitt.edu
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reproduction in any medium, provided the orineligible for TIL-based therapy because their TILs do not
expand sufficiently or because their tumors have lost
expression of antigens or MHC molecules or have
extremely low numbers of TILs. Cytokine-induced killer
(CIK) cells are a heterogeneous population of effector
CD8 T cells with diverse TCR specificities, possessing
non-MHC-restricted cytolytic activities against tumor
cells. Therefore, CIK cells can lyse tumor cells in a non-
MHC-restricted manner and can serve as an alternative
cellular immunotherapy. This review summarizes tech-
nical aspects of CIK, current clinical experiences and
future clinical utility.
The cellular characteristics of CIK
CIK cells are generated by in vitro expansion of peripheral
blood lymphocytes (PBL) using anti-CD3 antibodies and
IL-2. Short-term culture of human PBLs with IL-2 allows
for proliferation and development of effector NK and
nonspecific T-cells, with lymphokine-activated killer
(LAK) activity [6,7]. LAK activity enables lysis of fresh
tumor targets in a non-MHC restricted manner in vitro
and also exerts in vivo anti-tumor effects. Nonetheless,
using LAK cells as a tumor immunotherapy has not
achieved much success clinically and is hampered by
both the limited expansion of LAK cells in vitro and low
cytolytic activity in vivo [8-10]. The human clinical
extrapolation from murine immunotherapy modelstd. This is an Open Access article distributed under the terms of the Creative
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be necessary to allow adequate anti-tumor responses [11].
It is not practical to obtain such a large number of LAK
cells for immunotherapy in humans. In addition,
LAK-based therapy was limited by high toxicity due
to the required in vivo infusion of IL-2. A solution for this
problem was to induce more potent cytotoxic activities in
harvested T cells. For this purpose, agonistic monoclonal
antibodies (mAbs) against CD3 and IL-2 have been added
to the PBMC culture. In such culture, more than 1000
fold expansion of cells can be achieved over 21-day
in vitro culture. In addition, these cultured cells have
potent cytolytic activity and can lyse tumor cells [11]. The
lytic activity of these cells can be further increased by
adding other cytokines such as IFN-γ and IL-1β [11]. The
original culture conditions defining CIK activity was
modified by adding IFN-γ 24 h before addition of
anti-CD3 mAb and IL-2, and the term CIK cell was
used to distinguish them from conventional IL-2 activated
LAK cells [12]. With a substantial increase in cytotoxicity
on a per cell basis and a higher proliferative response, CIK
cells had a more than 70 fold increase in total cytolytic
activity per culture when compared with standard IL-
2-stimulated LAK cell activity [12].
Among expanded CIK cells, the cells with the greatest
cytotoxicity against tumor cell lines express both the
T-cell marker CD3 and the NK cell marker CD56.
CD3+CD56+cells are rare in uncultured PBLs [13],
consistent with the phenotype of resting naïve and
memory T cells. When PBLs are cultured under CIK
conditions for 21 days, more than 90% of the cells
expanded are CD3+ [14]. They are constituted by
about 70% CD8+ and 30% CD4+ cells. The percentage
of CD3+CD56+ cells also greatly increases and reaches
a plateau after approximately 21 day of culture to
more than 20 to 30% of the CIK cells, consistent with
the generation of effector T cells in these cultures.
Most of the CD3+CD56+ cells co-express CD2, TCRαβ,
and CD8 but are negative for CD4, the helper T cell
marker and CD16, an NK cell marker. The cytotoxicity
mediated by CD3+CD56+ cells does not depend on MHC,
similar to that mediated by NK cells. Interestingly,
antitumor activity is restricted to the CD3+CD56+CIK and
alloreactivity against HLA-mismatched PBMC is restricted
to the CD3+CD56− CIK [15]. These cells differ from NK
cells because they do not mediate antibody-dependent
cell-mediated cytotoxicity (ADCC). CD3+CD56+ cells
expanded under these culture conditions are derived from
CD3+CD56-T cells and not from CD3-CD56+NK cells
[16]. Following culture, CD3+CD8+ but not CD3+CD4+ T
cells express high levels of CD56. This is consistent with
the fact that effector CD8 T cells possess high levels of
cytotoxic activity [16]. In addition CIK cells are
CD45RA+, CCR7, CD62L weakly positive, CD11a+,CD27+, CD28+, macrophage inflammatory protein 1a+,
perforin+, Fas ligand+, suggesting these are largely
terminally differentiated memory T cells [16]. Further-
more, the Vβ repertoire in CIK cells at the end of culture
is of polyclonal pattern. Thus, the CIK culture condition
generated a heterogeneous population of effector CD8
T cells with diverse TCR specificity but possess non-
MHC-restricted cytolytic activities against tumor cells.
Molecular triggers of CIK cytolytic activities
CIK cells possess potent cytotoxic activities against a
number of tumor cell lines or freshly isolated tumor
samples, including acute myeloid leukemia, chronic
myeloid leukemia and B lymphoma cells [16-19]. Besides
hematopoietic cancer cells [20], CIK cells exert potent
in vivo antitumor effects on human solid tumors including
liver cancer [21], gastric cancer [22], lung cancer [23],
glioma [24] and others. In contrast, CIK cells demonstrate
little or no cytolytic activity against normal bone marrow
or spleen cells in vitro, with substantial specificity for
tumor cells [24,25].
Although CIK cells are capable of undergoing
degranulation upon stimulation with either agonistic
anti-CD3 mAbs or susceptible target tumor cells, the
molecules on malignant cells that stimulate cytolytic
activities of CIK cells do not involve MHC-TCR inter-
action. Tumor cell-triggered cytotolytic activities in CIK
can not be inhibited by neutralizing CD3 or HLA-class I
mAbs. In addition, cyclosporin (CsA) and FK506 inhibit
anti-CD3-mediated degranulation, but do not affect
cytotoxicity of CIK cells against tumor target cells [26].
CIK cell binding to target cells and formation of cellular
conjugates with tumor cells are required for CIK-
mediated cytotoxicity against tumor cell lines [27]. Cell
surface adhesion molecule leukocyte function associated
antigen-1 (LFA-1) is known to participate in effector/target
recognition and stable conjugate formation. CIK cells
express LFA-1 and the most susceptible tumor cells express
LFA-1 ligands such as ICAM-1, -2, and −3. CIK-tumor cell
conjugate formation and cytotoxicity against tumor cells
are strongly inhibited by anti–LFA-1 mAb, suggesting that
LFA-1 has a critical role in binding to target as well as in
enabling the cytotoxicity mediated by CIK cells [26,27].
Besides adhesion molecules, CIK cells express activating
NK receptors, including NKG2D, DNAX accessory
molecule-1 (DNAM-1), and low levels of NKp30. The
NKG2D ligands such as MIC A/B and ULBPs are highly
expressed on tumor cells [28]. Cell signaling through
NKG2D, DNAM-1, or NKp30 results in CIK cell
activation leading to degranulation and cytotoxicity.
Neutralization of DNAM-1, NKG2D, and NKp30 by
antibodies confirms that these molecules are involved
in the TCR-independent tumor cell recognition and killing
by CIK cells [26,27,29].
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The severe combined immunodeficiency (SCID) mouse
model has been used for testing non-MHC-restricted
antitumor effects with adoptive transfer of human CIK
cells [12]. CIK cell infusion significantly prolongs
survival of SCID mice injected with human lymphoma
cells when compared with control animals injected with
tumor cells alone or animals treated with LAK cells.
Thus CIK cells seem to have superior in vivo antitumor
activity in SCID mice, when compared with cells with
LAK activity [16]. Using the SCID model, CIK cells have
been shown to have in vivo antitumor effect against a
number of hematopoietic and solid tumors [30].
Mouse CIK cells also possess anti-tumor cytolytic
activities. When murine spleen cells are cultured under
CIK culture conditions for 21 days, the majority of the
cells are TCRαβ+ CD3+ CD8+ T cells [31]. Interestingly,
approximately 20% to 50% of the cells express the NK
markers NK1.1 and DX5, consistent with the phenotype
of effector CD8 T cells. Cytotoxicity is greatest among
cells expressing either NK1.1 or DX5. Expanded CD8+T
cells produce high levels of TH1-type cytokines such as
IFN-γ and inflammatory cytokines such as tumor necrosis
factor α.
The availability of murine CIK cells allows testing their
antitumor functions in immune-competent inbred mice.
Thirty minutes following intravenous injection, CIK cells
can be detected in the lungs, followed by distribution of
the cells to other sites including the liver and spleen,
within the next 16 hours. By 72 hours, significant numbers
of transferred CIK cells are found in cells infiltrating
tumor. CIK cells remain at the tumor site for more than
9 days. In addition, transferred mouse CIK cells demon-
strate potent antitumor effect against both allogeneic and
syngeneic transplanted tumor [32].Clinical studies
CIK cells have been evaluated as an adoptive cell im-
munotherapy for cancer patients in a number of clinical
trials (summarized in Table 1). Peripheral blood mono-
nuclear cells (PBMC) were isolated by apheresis. T cells
were then activated, expanded, and differentiated by
anti-CD3 in the presence of cytokines including IFN-γ,
IL-1α, and IL-2 for 14 to 21 days to generate CIK, which
were subsequently infused into patients (Figure 1). In
the first phase I clinical study, autologous CIK cells
transduced with the interleukin-2 gene were infused in
patients with metastatic renal cancer, colorectal cancer and
lymphoma [33]. Transfected CIK cells could be detected
for up to 2 weeks following infusion by analyzing expres-
sion of the IL-2 transgene. Six patients progressed, three
patients were stable, and one patient with lymphoma
developed a complete response. In three patients, WHOgrade 2 fever was observed, and no major side-effect was
observed despite the use of the IL-2 transgene in CIK cells.
CIK clinical studies were done on hematologic malig-
nancies. A Phase I trial of autologous CIK cells for the
treatment of patients with relapsed Hodgkin’s disease
and non-Hodgkin’s lymphoma was carried out on nine
patients with advanced Hodgkin’s disease (n=7) and
non-Hodgkin’s lymphoma (n=2), who had relapsed after
an autologous transplantation. Two patients had partial
responses, and another two patients had stabilization of
disease. Toxicity was minimal [14]. In another study, 6
advanced lymphomas were enrolled. One patient had
CR with a median follow-up of 33 months [38]. Signifi-
cant antitumor activity was reported against hematologic
malignancies after hematopoietic cell transplant. A phase
I study of allogeneic CIK cells in six leukemia patients
relapsing after allogeneic haematopoietic stem cell
transplantation (HSCT) was done. Acute GVHD (grade
I and II) was observed in four patients. One patient had
stable disease, one had hematologic improvement and
three achieved complete responses [35]. The feasibility of
CIK in patients with relapsed hematologic malignancies
after allogeneic HCT was explored in another study.
Eighteen patients were given CIK cell infusions at escalating
doses. Acute GVHD grade I-II was seen in 2 patients, and
1 patient had limited chronic GVHD. Five patients had
longer remissions. The therapy was well tolerated and
induced a low incidence of GVHD [40]. These phase I
clinical studies have yielded encouraging results and
demonstrated the safety of using CIK cells as immuno-
therapeutic approach.
We (JJ and CW) reported the effects of autologous
CIK cells together with chemotherapy on patients with
advanced gastric cancer (stage IV) [34]. Fifty-seven
patients were nonrandomly divided into two groups:
those receiving chemotherapy plus CIK biotherapy and
those treated with chemotherapy alone. Following CIK cell
infusion, serum levels of tumor markers were significantly
decreased, and the short-term curative effect and the
quality of life (QOL) were improved in the patients treated
by chemotherapy plus CIK cells when compared with
patients treated by chemotherapy alone. Moreover, the
2-year survival was prolonged in the group treated by
chemotherapy plus CIK cells when compared to the
group treated with chemotherapy alone. Our follow-up
study with a larger cohort of 156 patients further confirmed
the benefit of CIK therapy [39]. In another report, we
evaluated the clinical efficacy of chemotherapy when
applied in combination with CIK cell therapy compared to
chemotherapy alone [36]. Fifty-nine advanced non-small
cell lung cancer (NSCLC) patients were randomly divided
into two groups, chemotherapy alone (group A) and
chemotherapy plus CIK cell transfusion (group B).
Autologous CIK cells were induced from the patients’
Table 1 Published CIK cell clinical studies
Year Tumor type No. of cases Culture condition Authors
1999 Renal cell carcinoma Colorectal carcinoma Lymphoma 10 IFN-γ, anti-CD3, IL2 plus IL-2 transgene Schmidt-Wolf IG et al. [33]
2005 Lymphoma 9 IFN-γ, anti-CD3, and IL2 Leemhuis T et al. [14]
2006 Gastric carcinoma 57 IFN-γ, anti-CD3, IL2 and IL-1alpha Jiang JT et al. [34]
2007 Leukemia 11 IFN-γ, anti-CD3 and IL2 Introna M et al. [35]
2008 Non-small cell lung cancer 59 IFN-γ, anti-CD3, IL2 and IL-1alpha Wu CP et al. [36]
2009 Hepatocellular carcinoma 127 IFN-γ, anti-CD3, IL2 and IL-1lalpha Hui D et al. [37]
2009 Renal cell carcinoma and lymphoma 6 IFN-γ, anti-CD3, and IL2 Olioso P et al. [38]
2010 Gastric carcinoma 156 IFN-γ, anti-CD3, IL2, and IL-1alpha Jiang JT et al. [39]
2011 relapsed hematologic malignancies 18 IFN-γ, anti-CD3, and IL2 Laport GG et al. [40]
2012 Renal cell carcinoma 74 IFN-γ, anti-CD3, IL2, IL-1beta Liu L et al. [41]
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found that the QOL was improved in the patients treated
by chemotherapy plus CIK biotherapy when compared
with the patients treated by chemotherapy alone. The
overall response rate (ORR) was 43.3% and 44.8% in
groups A and B, respectively. The time to progression was
4.67 months in group A and 6.65 months in group B and
the median survival time was 11.0 months in group A and
15.0 months in group B. Compared to patients in group
A, the patients in group B had significantly longer pro-
gression-free survival (PFS) (p=0.042) and overall survival








Figure 1 Procedure for CIK preparation and infusion. Peripheral blood
activated, expanded, and differentiated by anti-CD3 in the presence of cyto
commonly called CIK, are then infused into patients.CIK cell transfusion patients. These studies demonstrate
that chemotherapy plus CIK cells has significant benefits
for patients who suffer from advanced gastric cancer and
lung cancer with no severe side-effects [34,36,39].
Two studies reported positive outcome for CIK therapy
for patients with hepatocellular carcinoma. A clinical trial
of postoperative adjuvant CIK immunotherapy following
radical resection of hepatocellular carcinoma was
reported. 127 patients were divided into 3 groups. After
radical resection of the tumor, immunotherapy with CIK
cells was performed for 3 courses in 41 patients (CIK-I
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kines including IFN-γ, IL-1α, and IL-2 for 14 to 21 days. These T cells,
Jiang et al. Journal of Translational Medicine 2013, 11:83 Page 5 of 9
http://www.translational-medicine.com/content/11/1/83other 43 patients received no postoperative adjuvant
therapy with CIK (the control group). The disease-free
survival rates were significantly higher in the CIK-I group
(p=0.001) and CIK-II group (p=0.004) than in the control
group. In a separate study, adoptive CIK immunotherapy
was also evaluated for reducing the recurrence of hepato-
cellular carcinoma (HCC) following minimally invasive
therapy. 85 HCC patients after transcatheter arterial
chemoembolization and radiofrequency ablation therapy
were randomized to the immunotherapy group and the
no adjuvant therapy group. The 1-year and 18-month
recurrence rates of the CIK group were 8.9% and 15.6%,
compared with 30.0% and 40.0% of the control group
(both p values<0.05).
CIK has also been tried on renal cell carcinoma
(RCC). The results of randomized study of autologous
cytokine-induced killer cell immunotherapy in metastatic
renal carcinoma have been reported recently [41]. 148
patients with metastatic clear cell RCC were randomized
and assigned to two groups: i.e. autologous CIK cell
immunotherapy (arm 1, n=74) and interleukin-2 treat-
ment in combination with IFN-α-2a (arm 2, n= 74). The
3-year PFS in arm 1 was significant greater than that in
arm 2 (18% versus 12%, p=0.031). And the 3-year OS in
arm 1 was also significantly greater than that in arm 2
(61% versus 23%, p<0.001). The median PFS and OS in
the CIK arm were significantly longer than those in the
control arm (PFS, 12 vs. 8 months, p=0.024; OS, 46 vs.
19 months, p<0.001). In another study, 5 metastatic kidney
carcinoma patients were enrolled. One patient had CR and
two patients had SD with a median follow-up of 33 months
[38]. The studies suggested that CIK cell immunotherapy
could improve the prognosis of metastatic clear cell RCC
with minor side effect.
Recently, the international registry on CIK Cells
(IRCC) has been established to collect data worldwide
and set standard criteria to report results from clinical
trials performed with CIK cells [42]. 11 clinical trials
with CIK cells were identified. Of the 384 patients,
where clinical response information was available, 24
patients showed a complete response, 27 patients
showed a partial response, 40 patients showed a minor
response. The total response rate (RR) was 91/384
reported patients, 161 patients had a stable disease, 129
patients had progressive disease. Side effects of CIK cell
treatment were minor. Disease-free survival rates were
significantly higher in patients treated with CIK cells
than in a control group without the CIK treatment.
We have recently reviewed the results published in
Chinese in a separate paper [43]. We collected results
from 24 clinical trials. Among these trials, 936 patients
were treated with CIK cells, including 525 men and 246
women. In five studies, CIK cells were co-cultured with
dendritic cells (DCs). The total number of CIK cells usedranged from 6×106 to 1.5×1010. Of the 563 patients,
where a clinical response was reported, 40 had CR, 126
had PR, 125 had MR, 135 had SD, 58 had PD. The total
response rate (RR) was 51.7% (291/563). The toxicities
were minimal. These results demonstrate that CIK cell
treatment is a promising and safe modality for treating
solid tumor.
Improving CIK therapy for epithelial cancer
The total antitumor cytolytic activity within cell culture
has been used as the sole marker for the success of CIK
generation [11,12]. This is influenced by T cell prolifera-
tion as well as the development of effector function.
Most of the studies use T cells cultured for 14 to 21 days.
Cytokines such as IFN-γ, IL-1, IL-2, IL-7, IL-15, and IL-12
have been evaluated for their ability to promote the CIK
generation [12,44-48]. According to the standard CIK
culture condition, IFN-γ is added at the beginning of the
culture and 24 h before the addition of anti-CD3 mAb
and IL-2 [12]. This is likely due to its role in promoting
IL-12 production by antigen presenting cells as well as its
ability to promote generation of autophagy and antigen
cross-presentation. In contrast, IL-2, IL-7, IL-15 and IL-12
can directly promote T cell proliferation/survival and
development of cytolytic effector functions. Other pro-
proliferative cytokines such as IL-21 and IL-23 need to be
tested separately or in combination with the cytokines
currently used in the CIK culture to examine whether they
can further promote CD8 T cell proliferation. In addition
to IL-1, other members of the IL-1 protein family such as
IL-18 and IL-33 promote CD8 and Th1 effector functions
[49,50]. These cytokines should be tested in CIK cultures
to determine whether they can promote cytolytic activities
of CIK cells. Furthermore, co-stimulatory molecules such
as CD28 and 4-1BB may also promote the efficient
production of CIK cells.
The existence of anti-tumor-specific T-cells in cancer
patients has been well documented. A potential mechanism
of action for CIK is enhancement of a recall antitumor
response by CD45RO+ memory T-cells. It is possible
that spontaneous tumor-specific T cells are expanded
with other non-specific T cells during CIK culture. Study
on CMV-specific T cells showed that the percentage of
CMV tetramer+ T cells did not significantly change from
the beginning to the end of the culture, suggesting that
CMV tetramer+ T cells expanded with similar efficiency
with the total CD8 T cells [27]. Thus, tumor-specific
components of CIK cells might be responsible for the
clinical benefit observed in some cancer patients [51].
Besides spontaneous antitumor cellular responses, some
chemotherapy regimens can induce tumor-specific T cells
in cancer patients by inducing the immunogenic death of
tumor cells or by engaging immune effector mechanisms
[52]. Consistent with this idea, our previous studies
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prolonged the survival of patients with advanced gastric
cancer [34,36,39]. The underlying mechanism needs to be
further studied in order to improve the combined therapy.
Future studies should focus on determining which chemo-
therapy regimen has the greatest synergy with CIK and
the associated mechanisms. A recent study showed that
autophagy is required for immunogenicity of tumor under
chemotherapy. This is due to the fact that suppression of
autophagy inhibits the release of adenosine triphosphate
(ATP), a key danger signal, from dying tumor cells [53,54].
Thus, thermotherapy that enhances autophagy in cancer
cells might synergize with CIK therapy.
CIK cells can be rendered tumor antigen-specific
by transduction with the retrovirus vectors encoding
either high affinity T cell receptors (TCR) or chimeric
antibody-T cell receptors (CAR) which recognize tumor
antigens [55]. Patients with melanoma have been treated
with T cells engineered to express high affinity TCRs
specific for melanoma antigens MART-1, gp100 and
NY-ESO-1 [56-58]. Objective clinical responses have
been reported, although some patients experienced
autoimmune responses, suggesting TCRs need to be
carefully selected [56,57]. CARs consist of the variable
region of a tumor specific monoclonal antibody fused to
an intracellular domains CD3 zeta and CD28. Autologous
activated T cells genetically engineered to express the
anti-CD19 CAR have been effective in treating patients
with lymphoma and chronic lymphocytic leukemia (CLL)
[59-62]. The side effect of this approach includes
elimination of normal B cells in these patients. Besides
the genetic engineering approach, tumor targeting can
also be made specific using a bi-specific antibody with one
part recognizing a surface tumor antigen and the other
part binding to a T cell membrane protein [63-65]. The
clinical efficacy of such approach remains to be evaluated.
It was originally reported that CIK cells could be
ex vivo expanded up to 1000 fold with standardized
conditions. However, it is a practical clinical problem
that individual variability exists in expansion rates. This
is likely due to immune suppression in cancer patients.
Myeloid derived suppressor cells contaminated in the
PBMC preparation or defective antigen presenting cells
might inhibit T cell expansion [66]. In addition, T cells
in cancer patients might be in a stage of anergy and
exhaustion [67]. Many new approaches should be tested
including using autologous dendritic cells (DC-CIK) or
allo-antigen presenting cells [68].
Due to their abilities to migrate to tumor site, CIK
cells can also be used to deliver bio-therapeutic agents
to the tumor site. One study combined CIK cells with an
oncolytic viral therapy and achieved directed delivery to,
and regression of, tumors in mouse models [69]. The CIK
cells retained their ability to traffic to and to infiltrate thetumor effectively before releasing the virus and the
modified vaccinia virus remains inactive until the CIK cell
encounters with the tumor. These results highlight the
idea that CIK cells can be used as a vehicle for delivering
biologic drugs directly to the tumor microenvironment. In
addition, finding ways to limit induction of autophagy and
resistance to immune-mediated effectors are also
promising strategies to couple with adoptive transfer of
CIK cells [70-72]. Trafficking of CIK cells is hard to
investigate in cancer patients. One approach to further
study the trafficking is to use various humanized mouse
models [73]. In vivo trafficking can also be studied by
tracking genetically engineered T cells upon infusion [74].
The survival of adoptively transferred CIK cells needs
to be further studied in patients and humanized mouse
models. CIK cells are composed of a mixture of effector
and central memory T cells. Effector T cells, although
possess potent immediate cytotoxic activities, produce a
large amount of IFN-γ and express high levels of
NKG2D, are known to be prone to apoptosis. Central
memory T cells and memory stem T cells, although
require restimulation in vivo to gain effector functions,
are more resistant to apoptosis than effector T cells
[75-78]. Therefore, studying the in vivo survival of
distinctive subsets of CIK cells and its relationship to
clinical outcome should help improve this therapy.
So far there is no reliable biomarker for estimating
clinical responses and predicting outcomes of CIK therapy.
Among many changes in the blood, it has been shown that
CD4/CD8 ratio and percentage of NK cells are significantly
increased in patients infused with CIK [34,36]. Whether
this or other markers correlate with clinical outcome is not
known [34,36]. The frequency of tumor antigen-specific T
cells should be studied in future clinical trials to examine
whether it is associated with better patient outcome. In
addition to blood marker, immunosuppressive molecules
that are expressed in the tumor microenvironment, such
as members of B7 family, should be further studied to
determine whether they can serve as prognostic markers
for the CIK therapy [79,80].
Conclusions
Current clinical studies suggest that CIK is a promising
and safe modality for treating malignancies. Multicenter
clinical trials are warranted to further establish the validity
of this therapeutic approach and optimize the CIK treat-
ment protocol. This therapy should be further improved
through increasing the specificity of CIK cells via
immunological and genetic engineering approaches
and identifying robust predictive biomarkers for patient
stratification. In addition, we believe combining chemother-
apy, radiotherapy or other immunotherapy approaches
with CIK will further improve cancer therapy and prolong
survival of cancer patients.
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